{"protocolSection": {"identificationModule": {"nctId": "NCT01251146", "orgStudyIdInfo": {"id": "EMR200006-515"}, "organization": {"fullName": "Merck KGaA, Darmstadt, Germany", "class": "INDUSTRY"}, "briefTitle": "A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension", "officialTitle": "Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Patients With Essential Hypertension"}, "statusModule": {"statusVerifiedDate": "2017-01", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-11"}, "primaryCompletionDateStruct": {"date": "2012-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-11-30", "studyFirstSubmitQcDate": "2010-11-30", "studyFirstPostDateStruct": {"date": "2010-12-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-11-01", "resultsFirstSubmitQcDate": "2012-11-01", "resultsFirstPostDateStruct": {"date": "2012-11-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-01-25", "lastUpdatePostDateStruct": {"date": "2017-03-08", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck KGaA, Darmstadt, Germany", "class": "INDUSTRY"}, "collaborators": [{"name": "Merck Serono Co., Ltd., China", "class": "INDUSTRY"}]}, "descriptionModule": {"briefSummary": "This is a Phase 4, prospective, multi-centric and randomized controlled study to compare the effects of bisoprolol and atenolol on resting heart rate (RHR) and sympathetic nervous system's (SNS) activity in subjects with essential hypertension."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Hypertension", "Bisoprolol", "Atenolol"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 177, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Bisoprolol", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Bisoprolol"]}, {"label": "Atenolol", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Atenolol"]}], "interventions": [{"type": "DRUG", "name": "Bisoprolol", "description": "Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.", "armGroupLabels": ["Bisoprolol"], "otherNames": ["Concor\u00ae"]}, {"type": "DRUG", "name": "Atenolol", "description": "Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.", "armGroupLabels": ["Atenolol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Baroreflex Sensitivity (BRS) at Attainment of Heart Rate Goal", "description": "Baroreflex sensitivity (BRS) is an important characteristic of baroreflex control and often noninvasively assessed by relating heart rate (HR) fluctuations to blood pressure (BP) fluctuations. Heart rate goal was defined as attainment of heart rate less than or equal to 65 beats per minute (bpm).", "timeFrame": "Baseline and attainment of heart rate goal (Week 2 or Week 4 or Week 6)"}, {"measure": "Change From Baseline in Baroreflex Sensitivity (BRS) at End of Follow-up", "description": "Baroreflex sensitivity (BRS) is an important characteristic of baroreflex control and often noninvasively assessed by relating heart rate (HR) fluctuations to blood pressure (BP) fluctuations. Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm.", "timeFrame": "Baseline and end of follow-up (Week 4 or Week 6 or Week 8)"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Heart Rate Variability (HRV) for Low Frequency Power (LF) and for High Frequency Power (HF) at Attainment of Heart Rate Goal and End of Follow-up", "description": "Heart rate variability (HRV) is used to describe the variations of both instantaneous HR and resting rate (RR) intervals and was evaluated for low frequency power (LF) and for high frequency power (HF). Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm.", "timeFrame": "Baseline, attainment of heart rate goal (Week 2 or Week 4 or Week 6) and end of follow-up (Week 4 or Week 6 or Week 8)"}, {"measure": "Change From Baseline in Ratio of Heart Rate Variability (HRV) for Low Frequency Power (LF) to Heart Rate Variability Power (HRV) for High Frequency (HF) (LF/HF) at Attainment of Heart Rate Goal and End of Follow-up", "description": "Heart rate variability (HRV) is used to describe the variations of both instantaneous HR and resting rate (RR) intervals and was evaluated for low frequency power (LF) and for high frequency power (HF). Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm.", "timeFrame": "Baseline, attainment of heart rate goal (Week 2 or Week 4 or Week 6) and end of follow-up (Week 4 or Week 6 or Week 8)"}, {"measure": "Number of Participants Attaining Heart Rate Goal at Dosage 1, 2 and 3 of Study Treatment", "description": "Dosage 1, 2 and 3 for bisoprolol group was defined as 5 mg, 7.5 mg and 10 mg once daily and for atenolol group as 50 mg, 75 mg and 100 mg once daily, respectively. Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm.", "timeFrame": "Baseline up to attainment of heart rate goal (Week 2 or Week 4 or Week 6)"}, {"measure": "Percentage of Participants Attaining Heart Rate Goal at Week 2, 4 and 6", "description": "Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm.", "timeFrame": "Attainment of heart rate goal (Week 2 or Week 4 or Week 6)"}, {"measure": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", "description": "AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition", "timeFrame": "Baseline up to end of follow-up (Week 4 or Week 6 or Week 8)"}, {"measure": "Number of Participants Compliant With Study Treatment", "description": "Participants compliant with study treatment were the participants who have completed the study treatment regimen.", "timeFrame": "Baseline up to end of follow-up (Week 4 or Week 6 or Week 8)"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects aged between 25-65 years\n* Subjects with essential hypertension (EH)\n* Subjects with systolic blood pressure (SBP) 140-160 millimeter of mercury (mmHg) and diastolic blood pressure (DBP) 90-100 mmHg\n* Subjects with normal sinus rhythm\n* Subjects with resting heart rate (RHR) greater than 70 bpm\n* Subjects who give written informed consent\n\nExclusion Criteria:\n\n* Subjects with atrial fibrillation (AF)/sick sinus syndrome (SSS)/atrioventricular block II-III Grade (AVB II-III) without pacemaker\n* Subjects with bradyarrhythmia/hypotension\n* Subjects with unstable angina pectoris (UAP)/acute myocardial infarction (AMI)/heart failure (HF) (New York Heart Association \\[NYHA\\] Class III - IV)\n* Subjects with uncontrolled diabetes mellitus (DM)\n* Subjects with bronchial asthma\n* Subjects with gastro-intestinal ulcer or skin ulcer\n* Subjects with liver dysfunction/renal impairment\n* Subjects treated with calcium channel blockers (except amlodipine) or other beta-blockers.\n* Subjects with glaucoma\n* Subjects with known allergic/intolerance to beta-blocker\n* Pregnant or lactating women\n* Subjects who had participated in another clinical study within the last 3 months\n* Subjects who have legal incapacity or limited legal capacity", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "25 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Gao Pingjin, Prof.", "affiliation": "Shanghai Institute of Hypertension", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Beijing Shi Jingshan Hospital", "city": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Shanghai Institute of Hypertension", "city": "Shanghai", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Bisoprolol", "description": "Bisoprolol was administered at a dose of 5 milligram (mg) once daily for 2 weeks. If the heart rate was less than or equal to 65 beats per minute (bpm) at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 7.5 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate was still greater than 65 bpm at Week 4, then the dose was further increased to 10 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose was administered for another 2 weeks (up to Week 8). If the heart rate was still greater than 65 bpm, then the treatment was ceased."}, {"id": "FG001", "title": "Atenolol", "description": "Atenolol was administered at a dose of 50 mg once daily for 2 weeks. If the heart rate was less than or equal to 65 bpm at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 75 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate still greater than 65 bpm at Week 4, then the dose was further increased to 100 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose administered for another 2 weeks. If the heart rate was still greater than 65 bpm, then the treatment was ceased."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "86"}, {"groupId": "FG001", "numSubjects": "91"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "83"}, {"groupId": "FG001", "numSubjects": "81"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "10"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "10"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Bisoprolol", "description": "Bisoprolol was administered at a dose of 5 milligram (mg) once daily for 2 weeks. If the heart rate was less than or equal to 65 beats per minute (bpm) at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 7.5 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate was still greater than 65 bpm at Week 4, then the dose was further increased to 10 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose was administered for another 2 weeks (up to Week 8). If the heart rate was still greater than 65 bpm, then the treatment was ceased."}, {"id": "BG001", "title": "Atenolol", "description": "Atenolol was administered at a dose of 50 mg once daily for 2 weeks. If the heart rate was less than or equal to 65 bpm at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 75 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate still greater than 65 bpm at Week 4, then the dose was further increased to 100 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose administered for another 2 weeks. If the heart rate was still greater than 65 bpm, then the treatment was ceased."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "86"}, {"groupId": "BG001", "value": "91"}, {"groupId": "BG002", "value": "177"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "45.44", "spread": "9.78"}, {"groupId": "BG001", "value": "46.30", "spread": "9.87"}, {"groupId": "BG002", "value": "45.88", "spread": "9.81"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "31"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "69"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "53"}, {"groupId": "BG002", "value": "108"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Baroreflex Sensitivity (BRS) at Attainment of Heart Rate Goal", "description": "Baroreflex sensitivity (BRS) is an important characteristic of baroreflex control and often noninvasively assessed by relating heart rate (HR) fluctuations to blood pressure (BP) fluctuations. Heart rate goal was defined as attainment of heart rate less than or equal to 65 beats per minute (bpm).", "populationDescription": "Intention to treat (ITT) population included all randomized participants who received at least 1 dose of study medication. \"N\" signifies those participants who were evaluated for this measure. \"n\" signifies those participants who were evaluated for this measure at the specified time point for each treatment arm group respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millisecond per millimeter of mercury", "timeFrame": "Baseline and attainment of heart rate goal (Week 2 or Week 4 or Week 6)", "groups": [{"id": "OG000", "title": "Bisoprolol", "description": "Bisoprolol was administered at a dose of 5 milligram (mg) once daily for 2 weeks. If the heart rate was less than or equal to 65 beats per minute (bpm) at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 7.5 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate was still greater than 65 bpm at Week 4, then the dose was further increased to 10 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose was administered for another 2 weeks (up to Week 8). If the heart rate was still greater than 65 bpm, then the treatment was ceased."}, {"id": "OG001", "title": "Atenolol", "description": "Atenolol was administered at a dose of 50 mg once daily for 2 weeks. If the heart rate was less than or equal to 65 bpm at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 75 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate still greater than 65 bpm at Week 4, then the dose was further increased to 100 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose administered for another 2 weeks. If the heart rate was still greater than 65 bpm, then the treatment was ceased."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "75"}, {"groupId": "OG001", "value": "79"}]}], "classes": [{"title": "Baseline (n=75,79)", "categories": [{"measurements": [{"groupId": "OG000", "value": "7.78", "spread": "2.92"}, {"groupId": "OG001", "value": "7.92", "spread": "3.26"}]}]}, {"title": "Change at attainment of heart rate goal (n=67,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.27", "spread": "3.67"}, {"groupId": "OG001", "value": "2.88", "spread": "4.05"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in Baroreflex Sensitivity (BRS) at End of Follow-up", "description": "Baroreflex sensitivity (BRS) is an important characteristic of baroreflex control and often noninvasively assessed by relating heart rate (HR) fluctuations to blood pressure (BP) fluctuations. Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm.", "populationDescription": "ITT population included all randomized participants who received at least 1 dose of study medication. \"N\" signifies those participants who were evaluated for this measure.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millisecond per millimeter of mercury", "timeFrame": "Baseline and end of follow-up (Week 4 or Week 6 or Week 8)", "groups": [{"id": "OG000", "title": "Bisoprolol", "description": "Bisoprolol was administered at a dose of 5 milligram (mg) once daily for 2 weeks. If the heart rate was less than or equal to 65 beats per minute (bpm) at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 7.5 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate was still greater than 65 bpm at Week 4, then the dose was further increased to 10 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose was administered for another 2 weeks (up to Week 8). If the heart rate was still greater than 65 bpm, then the treatment was ceased."}, {"id": "OG001", "title": "Atenolol", "description": "Atenolol was administered at a dose of 50 mg once daily for 2 weeks. If the heart rate was less than or equal to 65 bpm at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 75 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate still greater than 65 bpm at Week 4, then the dose was further increased to 100 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose administered for another 2 weeks. If the heart rate was still greater than 65 bpm, then the treatment was ceased."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "71"}, {"groupId": "OG001", "value": "66"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.08", "spread": "3.79"}, {"groupId": "OG001", "value": "3.31", "spread": "3.83"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Heart Rate Variability (HRV) for Low Frequency Power (LF) and for High Frequency Power (HF) at Attainment of Heart Rate Goal and End of Follow-up", "description": "Heart rate variability (HRV) is used to describe the variations of both instantaneous HR and resting rate (RR) intervals and was evaluated for low frequency power (LF) and for high frequency power (HF). Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm.", "populationDescription": "ITT population included all randomized participants who received at least 1 dose of study medication. \"N\" signifies those participants who were evaluated for this measure. \"n\" signifies those participants who were evaluated for this measure at the specified time point for each treatment arm group respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "millisecond square (ms^2)", "timeFrame": "Baseline, attainment of heart rate goal (Week 2 or Week 4 or Week 6) and end of follow-up (Week 4 or Week 6 or Week 8)", "groups": [{"id": "OG000", "title": "Bisoprolol", "description": "Bisoprolol was administered at a dose of 5 milligram (mg) once daily for 2 weeks. If the heart rate was less than or equal to 65 beats per minute (bpm) at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 7.5 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate was still greater than 65 bpm at Week 4, then the dose was further increased to 10 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose was administered for another 2 weeks (up to Week 8). If the heart rate was still greater than 65 bpm, then the treatment was ceased."}, {"id": "OG001", "title": "Atenolol", "description": "Atenolol was administered at a dose of 50 mg once daily for 2 weeks. If the heart rate was less than or equal to 65 bpm at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 75 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate still greater than 65 bpm at Week 4, then the dose was further increased to 100 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose administered for another 2 weeks. If the heart rate was still greater than 65 bpm, then the treatment was ceased."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "75"}, {"groupId": "OG001", "value": "79"}]}], "classes": [{"title": "HRV for LF at Baseline (n=75,79)", "categories": [{"measurements": [{"groupId": "OG000", "value": "261.80", "spread": "208.40"}, {"groupId": "OG001", "value": "322.09", "spread": "315.30"}]}]}, {"title": "Change for LF: heart rate goal (n=71,71)", "categories": [{"measurements": [{"groupId": "OG000", "value": "90.04", "spread": "352.97"}, {"groupId": "OG001", "value": "26.14", "spread": "416.51"}]}]}, {"title": "Change at end of follow-up for LF (n=71,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "89.40", "spread": "330.26"}, {"groupId": "OG001", "value": "-22.00", "spread": "295.54"}]}]}, {"title": "HRV for HF at Baseline (n=75,79)", "categories": [{"measurements": [{"groupId": "OG000", "value": "171.26", "spread": "161.43"}, {"groupId": "OG001", "value": "193.48", "spread": "216.06"}]}]}, {"title": "Change for HF: heart rate goal (n=71,71)", "categories": [{"measurements": [{"groupId": "OG000", "value": "148.91", "spread": "338.13"}, {"groupId": "OG001", "value": "136.67", "spread": "314.47"}]}]}, {"title": "Change at end of follow-up for HF (n=71,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "186.46", "spread": "288.53"}, {"groupId": "OG001", "value": "178.05", "spread": "375.70"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Ratio of Heart Rate Variability (HRV) for Low Frequency Power (LF) to Heart Rate Variability Power (HRV) for High Frequency (HF) (LF/HF) at Attainment of Heart Rate Goal and End of Follow-up", "description": "Heart rate variability (HRV) is used to describe the variations of both instantaneous HR and resting rate (RR) intervals and was evaluated for low frequency power (LF) and for high frequency power (HF). Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm.", "populationDescription": "ITT population included all randomized participants who received at least 1 dose of study medication. \"N\" signifies those participants who were evaluated for this measure. \"n\" signifies those participants who were evaluated for this measure at the specified time point for each treatment arm group respectively.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ratio", "timeFrame": "Baseline, attainment of heart rate goal (Week 2 or Week 4 or Week 6) and end of follow-up (Week 4 or Week 6 or Week 8)", "groups": [{"id": "OG000", "title": "Bisoprolol", "description": "Bisoprolol was administered at a dose of 5 milligram (mg) once daily for 2 weeks. If the heart rate was less than or equal to 65 beats per minute (bpm) at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 7.5 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate was still greater than 65 bpm at Week 4, then the dose was further increased to 10 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose was administered for another 2 weeks (up to Week 8). If the heart rate was still greater than 65 bpm, then the treatment was ceased."}, {"id": "OG001", "title": "Atenolol", "description": "Atenolol was administered at a dose of 50 mg once daily for 2 weeks. If the heart rate was less than or equal to 65 bpm at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 75 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate still greater than 65 bpm at Week 4, then the dose was further increased to 100 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose administered for another 2 weeks. If the heart rate was still greater than 65 bpm, then the treatment was ceased."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "75"}, {"groupId": "OG001", "value": "79"}]}], "classes": [{"title": "Baseline (n=75,79)", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.16", "spread": "1.89"}, {"groupId": "OG001", "value": "2.40", "spread": "1.96"}]}]}, {"title": "Change at attainment of heart rate goal (n=71,71)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.70", "spread": "1.76"}, {"groupId": "OG001", "value": "-0.90", "spread": "1.62"}]}]}, {"title": "Change at end of follow-up (n=71,66)", "categories": [{"measurements": [{"groupId": "OG000", "value": "-0.69", "spread": "2.08"}, {"groupId": "OG001", "value": "-1.15", "spread": "1.68"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Attaining Heart Rate Goal at Dosage 1, 2 and 3 of Study Treatment", "description": "Dosage 1, 2 and 3 for bisoprolol group was defined as 5 mg, 7.5 mg and 10 mg once daily and for atenolol group as 50 mg, 75 mg and 100 mg once daily, respectively. Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm.", "populationDescription": "ITT population included all randomized participants who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline up to attainment of heart rate goal (Week 2 or Week 4 or Week 6)", "groups": [{"id": "OG000", "title": "Bisoprolol", "description": "Bisoprolol was administered at a dose of 5 milligram (mg) once daily for 2 weeks. If the heart rate was less than or equal to 65 beats per minute (bpm) at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 7.5 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate was still greater than 65 bpm at Week 4, then the dose was further increased to 10 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose was administered for another 2 weeks (up to Week 8). If the heart rate was still greater than 65 bpm, then the treatment was ceased."}, {"id": "OG001", "title": "Atenolol", "description": "Atenolol was administered at a dose of 50 mg once daily for 2 weeks. If the heart rate was less than or equal to 65 bpm at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 75 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate still greater than 65 bpm at Week 4, then the dose was further increased to 100 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose administered for another 2 weeks. If the heart rate was still greater than 65 bpm, then the treatment was ceased."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "86"}, {"groupId": "OG001", "value": "91"}]}], "classes": [{"title": "Dosage 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "72"}, {"groupId": "OG001", "value": "72"}]}]}, {"title": "Dosage 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Dosage 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Attaining Heart Rate Goal at Week 2, 4 and 6", "description": "Heart rate goal was defined as attainment of heart rate less than or equal to 65 bpm.", "populationDescription": "ITT population included all randomized participants who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "Attainment of heart rate goal (Week 2 or Week 4 or Week 6)", "groups": [{"id": "OG000", "title": "Bisoprolol", "description": "Bisoprolol was administered at a dose of 5 milligram (mg) once daily for 2 weeks. If the heart rate was less than or equal to 65 beats per minute (bpm) at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 7.5 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate was still greater than 65 bpm at Week 4, then the dose was further increased to 10 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose was administered for another 2 weeks (up to Week 8). If the heart rate was still greater than 65 bpm, then the treatment was ceased."}, {"id": "OG001", "title": "Atenolol", "description": "Atenolol was administered at a dose of 50 mg once daily for 2 weeks. If the heart rate was less than or equal to 65 bpm at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 75 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate still greater than 65 bpm at Week 4, then the dose was further increased to 100 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose administered for another 2 weeks. If the heart rate was still greater than 65 bpm, then the treatment was ceased."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "86"}, {"groupId": "OG001", "value": "91"}]}], "classes": [{"title": "Week 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "83.72", "lowerLimit": "9.41", "upperLimit": "24.81"}, {"groupId": "OG001", "value": "79.12", "lowerLimit": "13.24", "upperLimit": "29.72"}]}]}, {"title": "Week 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "91.86", "lowerLimit": "3.58", "upperLimit": "15.11"}, {"groupId": "OG001", "value": "85.71", "lowerLimit": "8.04", "upperLimit": "22.26"}]}]}, {"title": "Week 6", "categories": [{"measurements": [{"groupId": "OG000", "value": "93.02", "lowerLimit": "2.85", "upperLimit": "13.63"}, {"groupId": "OG001", "value": "85.71", "lowerLimit": "8.04", "upperLimit": "22.26"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)", "description": "AE: any new untoward medical occurrence/worsening of pre-existing medical condition, whether or not related to study drug. SAE: Any AE that resulted in death; was life threatening; resulted in persistent/significant disability/incapacity; resulted in/prolonged an existing in-patient hospitalization; was a congenital anomaly/birth defect; or was a medically important condition", "populationDescription": "Safety population included all randomized participants who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline up to end of follow-up (Week 4 or Week 6 or Week 8)", "groups": [{"id": "OG000", "title": "Bisoprolol", "description": "Bisoprolol was administered at a dose of 5 milligram (mg) once daily for 2 weeks. If the heart rate was less than or equal to 65 beats per minute (bpm) at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 7.5 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate was still greater than 65 bpm at Week 4, then the dose was further increased to 10 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose was administered for another 2 weeks (up to Week 8). If the heart rate was still greater than 65 bpm, then the treatment was ceased."}, {"id": "OG001", "title": "Atenolol", "description": "Atenolol was administered at a dose of 50 mg once daily for 2 weeks. If the heart rate was less than or equal to 65 bpm at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 75 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate still greater than 65 bpm at Week 4, then the dose was further increased to 100 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose administered for another 2 weeks. If the heart rate was still greater than 65 bpm, then the treatment was ceased."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "86"}, {"groupId": "OG001", "value": "91"}]}], "classes": [{"title": "Number of participants with AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "6"}]}]}, {"title": "Number of participants with SAEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}]}]}]}, {"type": "SECONDARY", "title": "Number of Participants Compliant With Study Treatment", "description": "Participants compliant with study treatment were the participants who have completed the study treatment regimen.", "populationDescription": "ITT population included all randomized participants who received at least 1 dose of study medication.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Baseline up to end of follow-up (Week 4 or Week 6 or Week 8)", "groups": [{"id": "OG000", "title": "Bisoprolol", "description": "Bisoprolol was administered at a dose of 5 milligram (mg) once daily for 2 weeks. If the heart rate was less than or equal to 65 beats per minute (bpm) at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 7.5 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate was still greater than 65 bpm at Week 4, then the dose was further increased to 10 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose was administered for another 2 weeks (up to Week 8). If the heart rate was still greater than 65 bpm, then the treatment was ceased."}, {"id": "OG001", "title": "Atenolol", "description": "Atenolol was administered at a dose of 50 mg once daily for 2 weeks. If the heart rate was less than or equal to 65 bpm at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 75 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate still greater than 65 bpm at Week 4, then the dose was further increased to 100 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose administered for another 2 weeks. If the heart rate was still greater than 65 bpm, then the treatment was ceased."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "86"}, {"groupId": "OG001", "value": "91"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "83"}, {"groupId": "OG001", "value": "81"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Baseline up to end of follow-up (Week 4 or Week 6 or Week 8)", "eventGroups": [{"id": "EG000", "title": "Bisoprolol", "description": "Bisoprolol was administered at a dose of 5 milligram (mg) once daily for 2 weeks. If the heart rate was less than or equal to 65 beats per minute (bpm) at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 7.5 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate was still greater than 65 bpm at Week 4, then the dose was further increased to 10 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose was administered for another 2 weeks (up to Week 8). If the heart rate was still greater than 65 bpm, then the treatment was ceased.", "seriousNumAffected": 0, "seriousNumAtRisk": 86, "otherNumAffected": 6, "otherNumAtRisk": 86}, {"id": "EG001", "title": "Atenolol", "description": "Atenolol was administered at a dose of 50 mg once daily for 2 weeks. If the heart rate was less than or equal to 65 bpm at Week 2, then the initial dose was administered for another 2 weeks (up to Week 4). If the heart rate was greater than 65 bpm at Week 2, then the dose was further increased to 75 mg once daily for 2 weeks (up to Week 4). If the heart rate was less than or equal to 65 bpm at Week 4, the increased dose was administered for another 2 weeks (up to Week 6). If the heart rate still greater than 65 bpm at Week 4, then the dose was further increased to 100 mg once daily for 2 weeks (up to Week 6). If the heart rate was less than or equal to 65 bpm at Week 6, the increased dose administered for another 2 weeks. If the heart rate was still greater than 65 bpm, then the treatment was ceased.", "seriousNumAffected": 0, "seriousNumAtRisk": 91, "otherNumAffected": 6, "otherNumAtRisk": 91}], "otherEvents": [{"term": "Dizziness", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 91}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Elevated Triglyceride", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 91}]}, {"term": "Elevated Cholesterol", "organSystem": "Metabolism and nutrition disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 91}]}, {"term": "Bradycardia", "organSystem": "Cardiac disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Chest distress", "organSystem": "General disorders", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 86}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 91}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true}, "pointOfContact": {"title": "Merck KGaA Communication Center", "organization": "Merck Serono, a division of Merck KGaA", "email": "service@merckgroup.com", "phone": "+49-6151-72-5200"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000001262", "term": "Atenolol"}, {"id": "D000017298", "term": "Bisoprolol"}], "ancestors": [{"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000013565", "term": "Sympatholytics"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000058671", "term": "Adrenergic beta-1 Receptor Antagonists"}, {"id": "D000000319", "term": "Adrenergic beta-Antagonists"}, {"id": "D000018674", "term": "Adrenergic Antagonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M19589", "name": "Bisoprolol", "asFound": "Young Children", "relevance": "HIGH"}, {"id": "M4568", "name": "Atenolol", "asFound": "Allowing", "relevance": "HIGH"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M16344", "name": "Sympatholytics", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M29197", "name": "Adrenergic beta-1 Receptor Antagonists", "relevance": "LOW"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M20755", "name": "Adrenergic Antagonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}]}}, "hasResults": true}